Overview

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer

Phase:

Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

AstraZeneca